Key clinical point: In patients with prostate cancer, androgen deprivation therapy (ADT) use is associated with an increased risk of iron-deficiency anemia (IDA) compared with its nonuse.

Major finding: The incidence rate of IDA during the 3-year follow-up period was higher in patients receiving ADT vs. those not receiving ADT (1.66 vs. 1.01 per 100 person-years). After adjustment, the risk of IDA was higher in patients treated with ADT (adjusted hazard ratio, 1.62; 95% confidence interval, 1.24-2.12).

Study details: A Taiwanese population-based retrospective propensity-matched study of 10,893 patients with prostate cancer (patients receiving ADT, n = 7,262; not receiving ADT, n = 3,631).

Disclosures: The study did not receive any specific grant. The authors declared no conflict of interest.